ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2153

Ocular Scleral Pathology and Relationship with Autoimmune Diseases: Study of 101 Patients from a Single Universitary Centre

Lara Sanchez-Bilbao1, Iñigo Gonzalez-Mazon 2, Mónica Calderón-Goercke 3, DIANA PRIETO- PENA 2, Jose Luis Martín-Varillas 1, Belén Atienza-Mateo 1, Rosalia Demetrio 4, Miguel A Gonzalez-Gay 1 and Ricardo Blanco 1, 1Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, 2Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 3Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, 4Hospital Universitario Marqués de Valdecilla, Santander, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: ocular involvement and autoimmune diseases

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Ocular scleral pathology may be associated with autoimmune diseases. Our aim was to assess a) the epidemiological and clinical features and b) the relationship with immune-related diseases.

Methods: Observational study of unselected consecutive patients studied in a single reference University Hospital during the last ten years with: a) diagnosis of episcleritis and b) diagnosis of scleritis (Watson and Hayreh classification system, P. G. Watson, S. S. Hayreh, Br J Ophthalmol. 1976 Mar; 60(3): 163–191).
Patients were studied in a reference multidisciplinary unit (rheumatologist and ophthalmologist). Demographics features, clinical findings, complementary tests and treatment were recorded.

Results: We studied 101 (65 women/38 men) patients /202 eyes with diagnosis of scleral pathology (episcleritis=75; scleritis =26); mean age at diagnosis, 49.0±14.17 years. The mean follow-up was 3.68±5.30 years.Demographic baseline characteristics and clinical manifestations of these patients are shown in TABLE 1.
Diffuse anterior scleritis (n=17; 16.8%) was the most common type of scleritis, followed by nodular. In case of episcleritis, the most common was simple-form (n = 71; 70.3%).
Etiology was as follows: idiopathic (n=59, 58.4%), associated to systemic disease (SD-group) (n=32, 31.7%), and infectious (n=10, 9.9%). In SD-group, the main association was with Crohn’s disease (n=8; 7.9%), rheumatoid arthritis (n=6; 5.9%) and psoriatic arthritis (n=4; 3.9%).
Laboratory tests were also performed in all patients, mainly as screening of systemic diseases. Antinuclear antibodies (ANA) and rheumatoid factor (RF) were positive in 9 patients, followed by HLA-B27 7; 6.9%).
Attending to the treatment, 100% of patients received topical treatment as first-line therapy and 81.2% (n=81) NSAIDs. Another conventional immunosuppressor and biological treatment were required in 27.7% (n=28) and 6.9 (n=7) respectively. The main indication for biological therapy was the presence of concomitant systemic disease.
Some complications were reported, being keratitis (n=6; 5.9%) the most common.

Conclusion: The results obtained are reproducible to those published in international series, except a more frequent of Crohn’s disease and a less frequent of vasculitides. Scleral pathology is a frequent entity and it is necessary to exclude underlying systemic pathology.


Disclosure: L. Sanchez-Bilbao, None; I. Gonzalez-Mazon, None; M. Calderón-Goercke, None; D. PRIETO- PENA, None; J. Martín-Varillas, None; B. Atienza-Mateo, None; R. Demetrio, None; M. Gonzalez-Gay, Abbvie, 2, 5, 8, Celgene, 5, 8, Janssen, 2, MSD, 2, 5, 8, Pfizer, 5, 8, Roche, 2, 5, 8, Sanofi, 5, 8, Sobi, 5, 8; R. Blanco, None.

To cite this abstract in AMA style:

Sanchez-Bilbao L, Gonzalez-Mazon I, Calderón-Goercke M, PRIETO- PENA D, Martín-Varillas J, Atienza-Mateo B, Demetrio R, Gonzalez-Gay M, Blanco R. Ocular Scleral Pathology and Relationship with Autoimmune Diseases: Study of 101 Patients from a Single Universitary Centre [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/ocular-scleral-pathology-and-relationship-with-autoimmune-diseases-study-of-101-patients-from-a-single-universitary-centre/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ocular-scleral-pathology-and-relationship-with-autoimmune-diseases-study-of-101-patients-from-a-single-universitary-centre/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology